Lenz Therapeutics Inc. highlighted the commercial rollout of VIZZ, an FDA-approved prescription eye drop for presbyopia designed to improve near vision with once-daily dosing. The company said VIZZ launched in October 2025 and is widely available, supported by a sales team of more than 100 representatives targeting approximately 15,000 eye care professionals and a direct-to-consumer campaign featuring Sarah Jessica Parker. The presentation also summarized clinical data from the CLARITY studies indicating rapid onset and durability of near-vision improvement for up to 10 hours, and noted tolerability observations including no serious treatment-related adverse events reported in trials. Pricing details included $79 for a one-month supply (25 vials) and $198 for a three-month supply (75 vials), with cash-pay access and HSA/FSA eligibility. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lenz Therapeutics Inc. published the original content used to generate this news brief on February 23, 2026, and is solely responsible for the information contained therein.